| 34 | Different types of metastatic/recurrent cancers | 33 | mEHT + radiotherapy | CR = 2 (6.1%), Very good PR = 5 (15.2%), PR = 13 (39.4%), SD = 9 (27.3%), PD = 4 (12.1%). Three patients (9.1%) developed autoimmune toxicities. All these three ptients had long-lasting abscopal responses outside the irradiated area. | Chi, Mehta, et al. 2020 [173] |
| 35 | Advanced gastric cancer | 24 | mEHT + chemotherapy + ketogenic diet + oxygen therapy | CR = 22 (88%) Mean follow-up = 23.9 m, mean OS = 39.5 m, mean PFS = 36.5 m, | Iyikesici, 2020b [174] , |
| 36 | Various |
| mEHT + chemotherapy | The feasibility and success of oncothermia is proven. | Fiorentini 2020 [175] |
| 37 | GBM |
| mEHT + chemotherapy | The feasibility and success of oncothermia is proven. | Van Gool 2021 [176] |
| 38 | Rectal cancer | 120 | mEHT + radiotherapy + surgery | In mEHT group, 80.7% showed down-staging compared with 67.2% in non-mEHT group. | Kim 2021 [177] , |
| 39 | Gliomas | 164 | mEHT + chemotherapy + radiotherapy | CR + PR is 41.4% for mEHT and 33.4% for conventional therapies. | Fiorentini 2020 [178] |
| 40 | Gastrointestinal cancer | 34 | mEHT + chemotherapy | The feasibility and success of oncothermia is proven. | Garay 2020 [179] |
| 41 | Ovarian, cervical cancer |
| mEHT + chemotherapy + radiotherapy | The feasibility and success of oncothermia is proven. | Wookyeom 2018 [180] , |
| 42 | Breast cancer | 13 | mEHT + chemotherapy + surgery | The feasibility and success of oncothermia is proven. | Szasz AM 2020 [181] |
| 43 | Cervical cancer | 38 | mEHT + chemotherapy | Cox-regression for CTx + mEHT study-group, (Rs-variable time-ratio of start of mEHT compared to OS (overall survival) Coefficient = 6.1, CI (95%) = 7.96; StErr = 4.06, p = 0.13, Hazard = 449. | Lee 2020 [81] |
| 44 | Various sites | 277 | mEHT + chemotherapy | 52% of the entire group was subjected to result analysis. 48% was not traceable. The result of the 52% was 21.5% PR, 36% SD, 28.9% PD, and 12.6% exitus. So 58.5% of the patients showed either stable disease or partial remission. | Lee 2013 [182] |
| 45 | Various sites | 784 | mEHT + chemotherapy + radiotherapy + surgery | Preliminary results show promising survival trajectories. mEHT is a safe treatment with very few adverse events or side effects, allowing patients to maintain a higher quality of life. | Parmar 2020 [183] |
| 46 | Various sites |
| mEHT + chemotherapy + radiotherapy | Planned trial | Arrojo 2020 [184] |
| 47 | Various sites |
| mEHT + chemotherapy + radiotherapy | The feasibility and success of oncothermia is proven. | Szasz AM 2019 [143] |
| 48 | Brain tumor | 54 | mEHT + chemotherapy | mEHT strongly and significantly enhances the efficacy of the ddTMZ 21/28 d regimen (p = 0.011), with a maximum attainable MST of 10.10 months (95%CI 9.10 to 11.10). | Roussakow 2017 [185] |